Infants are at increased risk for serious complications from influenza, with morbidity rates exceeding even adults >65 years. Unfortunately, influenza vaccines are ineffective in infants <6 months of age. This biologically vulnerable group relies on maternal antibody for protection. Public health officials advocate maternal immunization;however, there is no data on which type of maternal influenza vaccine best protects infants. We seek to compare maternal response to the systemic inactivated influenza vaccine (TIV) and the intranasal live-attenuated influenza vaccine (LAIV). Because the lactating mammary gland is part of mucosa-associated lymphoid tissue, we hypothesize that mucosally-administered LAIV will elicit higher levels of anti-influenza immunity in breast milk than vaccination with the injeced TIV. We will evaluate levels of influenza-specific antibodies and cellular immunity in blood and breast milk. We also will compare levels of influenza-specific responses in TIV and LAIV recipients. Finally, we will perform gene expression experiments to identify gene expression patterns induced after vaccination to further understand differences in innate and adaptive immune responses. Our data will provide a comprehensive analysis of the mechanisms underlying immune protection during breastfeeding. Moreover, the experience and knowledge gained from this proposal will lay the foundation for an R01 application for support for further investigations of how to optimize this maternal vaccination strategy for the protection of infants against influenza and other infectious diseases.

Public Health Relevance

Maternal immunization with influenza vaccine has the potential to protect infants less than six months of age, a vulnerable age group at risk for seriou complications and death and for whom vaccine is not available. This proposal seeks to evaluate the immune response in breast milk following maternal immunization with the injected inactivated influenza vaccine compared to the nasal spray live attenuated influenza vaccine. The results will increase our understanding of how breast milk provides immune protection and will lay the foundation for larger clinical studies to determine which maternal immunization strategy is most efficacious in protecting infants.

National Institute of Health (NIH)
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Mentored Patient-Oriented Research Career Development Award (K23)
Project #
Application #
Study Section
Pediatrics Subcommittee (CHHD)
Program Officer
Raiten, Daniel J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Children's Hospital of Los Angeles
Los Angeles
United States
Zip Code
Le Doare, Kirsty; Holder, Beth; Bassett, Aisha et al. (2018) Mother's Milk: A Purposeful Contribution to the Development of the Infant Microbiota and Immunity. Front Immunol 9:361
Pannaraj, Pia S; Ly, Melissa; Cerini, Chiara et al. (2018) Shared and Distinct Features of Human Milk and Infant Stool Viromes. Front Microbiol 9:1162
Wacharachaisurapol, Noppadol; Bender, Jeffrey M; Wang, Larry et al. (2017) Abdominal Actinomycosis in Children: A Case Report and Literature Review. Pediatr Infect Dis J 36:e76-e79
Smit, Michael A; Wang, Hai-Lin; Kim, Edward et al. (2016) Influenza Vaccine is Protective Against Laboratory-confirmed Influenza in Obese Children. Pediatr Infect Dis J 35:440-5
Pannaraj, Pia S; Bard, Jennifer Dien; Cerini, Chiara et al. (2015) Pediatric carbapenem-resistant Enterobacteriaceae in Los Angeles, California, a high-prevalence region in the United States. Pediatr Infect Dis J 34:11-6
Cheung, Susan; Wang, Hai-Lin; Mascola, Laurene et al. (2015) Parental perceptions and predictors of consent for school-located influenza vaccination in urban elementary school children in the United States. Influenza Other Respir Viruses 9:255-62
Pannaraj, Pia S; Wang, Hai-Lin; Rivas, Hector et al. (2014) School-located influenza vaccination decreases laboratory-confirmed influenza and improves school attendance. Clin Infect Dis 59:325-32